Economics

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

Retrieved on: 
Wednesday, February 21, 2024

Non-GAAP operating loss(1) totaled $22.5 million, or negative 11 percent of sales, compared to $2.4 million or negative 1 percent of sales.

Key Points: 
  • Non-GAAP operating loss(1) totaled $22.5 million, or negative 11 percent of sales, compared to $2.4 million or negative 1 percent of sales.
  • Adjusted EBITDA(1) was $4.3 million, or 2 percent of sales, compared to $25.7 million, or 11 percent of sales.
  • Net income (loss): GAAP net loss was $30.0 million, compared to net loss of $15.9 million.
  • Sales: In the United States, GAAP sales include a $25.1 million deferral relating to Tandem Choice, compared to a deferral of $3.5 million.

Gray Decision Intelligence Experienced Notable Growth in 2023

Retrieved on: 
Wednesday, February 21, 2024

Gray Decision Intelligence (Gray DI), the leading provider of academic program evaluation software, today announced significant growth in 2023.

Key Points: 
  • Gray Decision Intelligence (Gray DI), the leading provider of academic program evaluation software, today announced significant growth in 2023.
  • Gray DI’s Program Evaluation System (PES) software now empowers investment in academic programs that drive student success and enrollment growth at over 150 colleges and universities nationwide.
  • “As higher education continues to evolve, Gray DI remains dedicated to empowering institutions with the data and insights needed for strategic growth and sustainability,” said Robert Atkins, CEO and Founder of Gray Decision Intelligence.
  • “We recognize the pivotal role of decision intelligence in providing precise, reliable, and accurate insights that empower institutions.

Tachyum Demonstrates PMU Running on Prodigy FPGA Emulation System

Retrieved on: 
Tuesday, February 20, 2024

Tachyum ® today announced that it has added a Performance Monitoring Unit (PMU) to its Prodigy® FPGA emulation system, empowering customers and partners with the ability to address bottlenecks and better optimize Prodigy performance for all applications and workloads.

Key Points: 
  • Tachyum ® today announced that it has added a Performance Monitoring Unit (PMU) to its Prodigy® FPGA emulation system, empowering customers and partners with the ability to address bottlenecks and better optimize Prodigy performance for all applications and workloads.
  • The PMU is an essential tool for collecting information about performance bottlenecks.
  • It offers the ability to record a wide range of events that encompass every aspect of the Prodigy Universal Processor without slowing down the application itself.
  • The PMU’s wide range of performance counters – supported by both software C-model and FPGA – facilitates both system debugging and performance tuning.

Sunnova Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024

Sunnova Energy International Inc. ("Sunnova") (NYSE: NOVA), a leading adaptive energy services company, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sunnova Energy International Inc. ("Sunnova") (NYSE: NOVA), a leading adaptive energy services company, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue increased to $720.7 million, or by $163.0 million, for the year ended December 31, 2023 compared to the year ended December 31, 2022.
  • As of December 31, 2023, Sunnova had total cash of $494.4 million, including restricted and unrestricted cash.
  • Sunnova is hosting a conference call for analysts and investors to discuss its fourth quarter and full year 2023 results at 8:00 a.m. Eastern Time, on February 22, 2024.

Jumio Announces Igor Beckerman as Chief Financial Officer

Retrieved on: 
Tuesday, February 20, 2024

Jumio , the leading provider of automated, end-to-end identity verification, risk assessment and compliance solutions, today announced the addition of Igor Beckerman as chief financial officer.

Key Points: 
  • Jumio , the leading provider of automated, end-to-end identity verification, risk assessment and compliance solutions, today announced the addition of Igor Beckerman as chief financial officer.
  • Beckerman’s appointment comes at a pivotal time for Jumio, as its market-leading, AI-powered solutions are reaching record-breaking automation and quality rates.
  • “The identity landscape is facing a seismic upheaval, and Igor joining our team of innovators is just another step we’re taking to ensure Jumio remains the clear leader in this space,” said Jumio CEO Robert Prigge.
  • “I’m thrilled to join Jumio at such an integral moment in the company’s evolution and look forward to helping make 2024 the company’s best year yet,” Beckerman said.

Next Health Expands: Three New Locations Set to Redefine Southern California's Wellness Landscape

Retrieved on: 
Wednesday, February 21, 2024

Next Health , a trailblazer in health optimization and longevity, has entered a multi-unit area development agreement with new operators to expand its presence across Southern California.

Key Points: 
  • Next Health , a trailblazer in health optimization and longevity, has entered a multi-unit area development agreement with new operators to expand its presence across Southern California.
  • View the full release here: https://www.businesswire.com/news/home/20240220769014/en/
    Next Health the leader in health optimization and longevity services.
  • Aligned with the partners’ capabilities, Next Health ensures the expert delivery of its innovative approach to health optimization and longevity, exceeding the high expectations set by the Southern California community.
  • For those eager to join the forefront of the next wave in health and wellness, explore franchising opportunities at the Next Health Franchise website or contact them via email at [email protected] .

Modified Release Neurology Therapeutics Report 2024 - Neurology Therapeutics Advance with Modified Release Formulation - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024

The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.
  • Data mining technologies, combined with data from genomics, combinational chemistry and outcome-based medicine, provide opportunities to search for new patterns.
  • The majority of projects/products are marked by a contractual relationship between the formulation IP developer/holder and the drug developer.
  • Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles.

Cessna Grand Caravan EX Amphibian extends reach in Southeast Asia with delivery in Malaysia

Retrieved on: 
Sunday, February 18, 2024

Textron Aviation today announced the delivery of a new Cessna Grand Caravan EX Amphibian turboprop to Malaysian property developer, Ikhasas Sdn Bhd, via its subsidiary company Oriental Sky Sdn Bhd.

Key Points: 
  • Textron Aviation today announced the delivery of a new Cessna Grand Caravan EX Amphibian turboprop to Malaysian property developer, Ikhasas Sdn Bhd, via its subsidiary company Oriental Sky Sdn Bhd.
  • This will be the country’s first amphibious airplane operation in recent history after it gained necessary approvals from the Civil Aviation Authority of Malaysia to launch domestic operations in 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240216837400/en/
    Oriental Sky’s Grand Caravan EX Amphibian (Photo: Business Wire)
    The Cessna Grand Caravan EX Amphibian is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company.
  • At the same time, we preserve the islands’ pristine environment and natural forests which would otherwise be felled for airport construction.”
    “We are honored for Grand Caravan EX Amphibian to be selected.

MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space

Retrieved on: 
Tuesday, February 20, 2024

The funding will be used to drive further commercialization of MIP Discovery’s novel synthetic affinity reagents within the cell and gene therapy space, with the Company working alongside leading industry players to develop novel tools aligned with critical applications.

Key Points: 
  • The funding will be used to drive further commercialization of MIP Discovery’s novel synthetic affinity reagents within the cell and gene therapy space, with the Company working alongside leading industry players to develop novel tools aligned with critical applications.
  • The funds will also support recruitment efforts to expand in-house cell and gene therapy expertise.
  • Taking the industry beyond the limitations of biological reagents, MIP Discovery’s synthetic antibody alternatives offer a fresh approach to downstream processing for cell and gene therapy developers.
  • We are delighted to be further backing MIP as they are making significant technical progress.”
    To learn more about how MIP Discovery is enabling cell and gene therapy developers, please visit https://mipdiscovery.com/cell-and-gene-therapy-enablers/ .

Global Times: How two sessions serve as bridge between people and government, help authorities formulate policies

Retrieved on: 
Friday, March 8, 2024

Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.

Key Points: 
  • Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.
  • In 2021, China also for the first time included a rare disease treatment in its National Reimbursement Drug List.
  • These moves together benefited thousands of Chinese suffering from rare diseases, including spinal muscular atrophy (SMA) patient Zhang Jianuo and his parents.
  • Motions and proposals during the two sessions are crucial pathways for addressing issues impacting people's livelihood, and they're becoming increasingly effective.